6 and 7). As showed in Table 2, the immunizer and potential donors share the same beta subunit in the HLA DQ molecule (DQB1*03:01), however combined to different alpha subunits. Such beta subunit presents an

only potentially immunogenic eplet: 45EV. Nevertheless, as the MFI value of the HLA heterodimer DQA1*02:01–DQB1*03:01 of the potential donors is 921, the immunological risk is low for class II HLA. Contrariwise, we were able to detect a strong reactivity against A*68:02, representing a high immunological risk for antibody-mediated rejection. As there is no agreement upon current CDC assay with the flow cytometry crossmatch and SPA results, we believe that the recipient has a mixture of antibodies with a prevalence of non-fixing complement isotypes, Trichostatin A or the titles of the fixing complement antibodies present in the current serum were not enough to activate the classic pathway of the complement system. Thus, the potential donors’ allele A*68:02 is considered one of the unacceptable mismatches for this recipient. As the calculated PRA was 91%, this case exemplifies the importance of using the Acceptable Mismatch approach. The implementation of the EpHLA program this website will allow a simple and automated analysis

of antibody data using the HLAMatchmaker algorithm and prevent the many laborious manual steps used in the current analyses. Based on the HLA types of the recipient/donor pair and the SPA result, it is possible to generate reports automatically which will support the transplantation team to define the risk of developing antibody-mediated rejection. The automated analysis is important to increase the efficiency in generating results with at least the same degree of accuracy [19]. Automation will certainly decrease the incidence of administrative errors and facilitate the information management within the organization [20]. In conclusion, the EpHLA program integrates SPA results and the HLAMatchmaker algorithm in

selleck inhibitor an automated histocompatibility analysis. The program will certainly benefit the donor selection and risk assessment for HLA sensitized recipients. The work was supported by the Immunogenetics and Molecular Biology Laboratory from UFPI. Thanks to CNPq for the scholarship granted to Herton Luiz Alves Sales Filho. The authors also acknowledge João Batista de Oliveira Silva Jr. for his corrections of the English version in preparation of the manuscript. “
“Since the introduction of potent immunosuppressants such as calcineurin inhibitors and improved immunological matching, the risk of acute transplant rejection has been reduced considerably. However, despite a wide range of immunosuppressive agents, severe episodes of rejection still occur and chronic allograft rejection still poses a significant problem [1] and [2].